You are here: Industry Insights > Eisai

News List

Eisai to develop cognitive function test with Cogstate biospectrumasia
September 05, 2019
Eisai will aim to raise awareness of cognitive function by developing and making widely available the CBB in Japan jointly with Cogstate
Eisai teams up with Merck to tackle NTDs in Kenya biospectrumasia
August 29, 2019
Eisai seeks to contribute to the health and welfare of people in developing and emerging countries.
Eisai Appoints Global Clinical Quality Assurance VP contractpharma
August 27, 2019
Dr. Chaturvedi responsible for developing, implementing and monitoring global policies and procedures to assure worldwide compliance with GCPs.
Eisai, Merck receive breakthrough therapy designation from FDA biospectrumasia
July 23, 2019
For LENVIMA (lenvatinib) plus KEYTRUDA (pembrolizumab) Combination Treatment as Potential First-Line Treatment of Patients with Advanced Unresectable Hepatocellular Carcinoma Not Amenable to Locoregional Treatment
China approves anti-cancer agent by Eisai biospectrumasia
July 18, 2019
Halaven is a halichondrin class microtubule dynamics inhibitor with a distinct binding profile.
Eisai Centre for G2D2 commences operation towards dementia treatment biospectrumasia
July 16, 2019
A focused drug discovery approach that integrates human genetics, data science, precision chemistry
Eisai collaborates with University of Dundee for cancer drug discovery biospectrumasia
July 09, 2019
Targeted protein degradation towards cancer drug discovery
Eisai forms PROTACs research collaboration pharmaceutical-technology
July 09, 2019
Eisai has formed a research collaboration to support oncology drug discovery using proteolysis targeting chimeras (PROTAC), which comprise two covalently linked protein-binding molecules.
Eisai Announces Vice President, U.S. Medical Affairs, Oncology Business Group Appointment americanpharmaceuticalreview
May 22, 2019
Eisai announced the immediate appointment of Dr. Luca Dezzani as Vice President, U.S. Medical Affairs, Oncology Business Group.
Eisai to sell anti-rheumatic injection in Japan biospectrumasia
May 13, 2019
Eisai Co., Ltd. has entered into a license agreement with medac Gesellschaft für klinische Spezialpräparate mbH (Medac) for the commercialization of its anti-rheumatic agent methotrexate (MTX) subcutaneous injection (pre-filled syringe) in Japan.

Previous page 1 2 3 4 5 6 7 8 9 10 Next page